Oxford University and AstraZeneca to restart the COVID 19 Vaccine trial.

By Ishank Katyal

London: AstraZeneca, a UK based pharmaceuticals giant announced on Saturday 5th September that they are going to resume the COVID- 19 vaccine trials alongside UK after the confirmation by Medicines Health Regulatory Authority (MHRA) after the pause caused by an unexpected volunteer illness in UK.
The company, however is working alongside Oxford University to make the chemical in the race of COVID vaccine.
AstraZeneca announced on Wednesday that the company has paused the operations due to unexpected illness in UK.
“Clinical trials for the AstraZeneca Oxford Coronavirus vaccine, AZD1222, have resumed in UK following the confirmation by the Medicines Health Regulatory Authority (MHRA) that it was safe to do so.” The company said in a statement.
An independent committee was held to review the safety, which was the routine step for World Health Organization.
AstraZeneca said that the committee “has concluded its investigations and recommended to MHRA that the operations in UK are safe to resume. “
In United States, AstraZeneca has begun hiring over 30,000 volunteers on August 31 and some smaller groups in Brazil and other parts of Latin America for the Phase 3 trials.
The AZD1222 uses the weakened version of the common cold causing Adenovirus vaccine to spike protein in cells.
After vaccination, this protein is developed inside the human body, which helps the immune system to fight Coronavirus.